Cargando…
A multi-center study of high dose Aldesleukin (Proleukin(® )(HD IL-2) + Vemurafenib Zelboraf(® )) therapy in patients with BRAF(V600 )mutation positive metastatic melanoma (proclivity 01)
| Autores principales: | , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288741/ http://dx.doi.org/10.1186/2051-1426-2-S3-P77 |
| _version_ | 1782352017264476160 |
|---|---|
| author | Clark, Joseph Flaherty, Lawrence Ernstoff, Marc Koon, Henry Milhem, Mohammed Militello, Gerald Agarwala, Sanjiv Curti, Brendan Cranmer, Lee Lao, Christopher D Logan, Theodore F Lutzky, Jose Rudrapatna, Venkatesh Daniels, Gregory Taback, Bret Aung, Sandra Lowder, James Lawson, David |
| author_facet | Clark, Joseph Flaherty, Lawrence Ernstoff, Marc Koon, Henry Milhem, Mohammed Militello, Gerald Agarwala, Sanjiv Curti, Brendan Cranmer, Lee Lao, Christopher D Logan, Theodore F Lutzky, Jose Rudrapatna, Venkatesh Daniels, Gregory Taback, Bret Aung, Sandra Lowder, James Lawson, David |
| author_sort | Clark, Joseph |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-4288741 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2014 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-42887412015-01-15 A multi-center study of high dose Aldesleukin (Proleukin(® )(HD IL-2) + Vemurafenib Zelboraf(® )) therapy in patients with BRAF(V600 )mutation positive metastatic melanoma (proclivity 01) Clark, Joseph Flaherty, Lawrence Ernstoff, Marc Koon, Henry Milhem, Mohammed Militello, Gerald Agarwala, Sanjiv Curti, Brendan Cranmer, Lee Lao, Christopher D Logan, Theodore F Lutzky, Jose Rudrapatna, Venkatesh Daniels, Gregory Taback, Bret Aung, Sandra Lowder, James Lawson, David J Immunother Cancer Poster Presentation BioMed Central 2014-11-06 /pmc/articles/PMC4288741/ http://dx.doi.org/10.1186/2051-1426-2-S3-P77 Text en Copyright © 2014 Clark et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| spellingShingle | Poster Presentation Clark, Joseph Flaherty, Lawrence Ernstoff, Marc Koon, Henry Milhem, Mohammed Militello, Gerald Agarwala, Sanjiv Curti, Brendan Cranmer, Lee Lao, Christopher D Logan, Theodore F Lutzky, Jose Rudrapatna, Venkatesh Daniels, Gregory Taback, Bret Aung, Sandra Lowder, James Lawson, David A multi-center study of high dose Aldesleukin (Proleukin(® )(HD IL-2) + Vemurafenib Zelboraf(® )) therapy in patients with BRAF(V600 )mutation positive metastatic melanoma (proclivity 01) |
| title | A multi-center study of high dose Aldesleukin (Proleukin(® )(HD IL-2) + Vemurafenib Zelboraf(® )) therapy in patients with BRAF(V600 )mutation positive metastatic melanoma (proclivity 01) |
| title_full | A multi-center study of high dose Aldesleukin (Proleukin(® )(HD IL-2) + Vemurafenib Zelboraf(® )) therapy in patients with BRAF(V600 )mutation positive metastatic melanoma (proclivity 01) |
| title_fullStr | A multi-center study of high dose Aldesleukin (Proleukin(® )(HD IL-2) + Vemurafenib Zelboraf(® )) therapy in patients with BRAF(V600 )mutation positive metastatic melanoma (proclivity 01) |
| title_full_unstemmed | A multi-center study of high dose Aldesleukin (Proleukin(® )(HD IL-2) + Vemurafenib Zelboraf(® )) therapy in patients with BRAF(V600 )mutation positive metastatic melanoma (proclivity 01) |
| title_short | A multi-center study of high dose Aldesleukin (Proleukin(® )(HD IL-2) + Vemurafenib Zelboraf(® )) therapy in patients with BRAF(V600 )mutation positive metastatic melanoma (proclivity 01) |
| title_sort | multi-center study of high dose aldesleukin (proleukin(® )(hd il-2) + vemurafenib zelboraf(® )) therapy in patients with braf(v600 )mutation positive metastatic melanoma (proclivity 01) |
| topic | Poster Presentation |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288741/ http://dx.doi.org/10.1186/2051-1426-2-S3-P77 |
| work_keys_str_mv | AT clarkjoseph amulticenterstudyofhighdosealdesleukinproleukinhdil2vemurafenibzelboraftherapyinpatientswithbrafv600mutationpositivemetastaticmelanomaproclivity01 AT flahertylawrence amulticenterstudyofhighdosealdesleukinproleukinhdil2vemurafenibzelboraftherapyinpatientswithbrafv600mutationpositivemetastaticmelanomaproclivity01 AT ernstoffmarc amulticenterstudyofhighdosealdesleukinproleukinhdil2vemurafenibzelboraftherapyinpatientswithbrafv600mutationpositivemetastaticmelanomaproclivity01 AT koonhenry amulticenterstudyofhighdosealdesleukinproleukinhdil2vemurafenibzelboraftherapyinpatientswithbrafv600mutationpositivemetastaticmelanomaproclivity01 AT milhemmohammed amulticenterstudyofhighdosealdesleukinproleukinhdil2vemurafenibzelboraftherapyinpatientswithbrafv600mutationpositivemetastaticmelanomaproclivity01 AT militellogerald amulticenterstudyofhighdosealdesleukinproleukinhdil2vemurafenibzelboraftherapyinpatientswithbrafv600mutationpositivemetastaticmelanomaproclivity01 AT agarwalasanjiv amulticenterstudyofhighdosealdesleukinproleukinhdil2vemurafenibzelboraftherapyinpatientswithbrafv600mutationpositivemetastaticmelanomaproclivity01 AT curtibrendan amulticenterstudyofhighdosealdesleukinproleukinhdil2vemurafenibzelboraftherapyinpatientswithbrafv600mutationpositivemetastaticmelanomaproclivity01 AT cranmerlee amulticenterstudyofhighdosealdesleukinproleukinhdil2vemurafenibzelboraftherapyinpatientswithbrafv600mutationpositivemetastaticmelanomaproclivity01 AT laochristopherd amulticenterstudyofhighdosealdesleukinproleukinhdil2vemurafenibzelboraftherapyinpatientswithbrafv600mutationpositivemetastaticmelanomaproclivity01 AT logantheodoref amulticenterstudyofhighdosealdesleukinproleukinhdil2vemurafenibzelboraftherapyinpatientswithbrafv600mutationpositivemetastaticmelanomaproclivity01 AT lutzkyjose amulticenterstudyofhighdosealdesleukinproleukinhdil2vemurafenibzelboraftherapyinpatientswithbrafv600mutationpositivemetastaticmelanomaproclivity01 AT rudrapatnavenkatesh amulticenterstudyofhighdosealdesleukinproleukinhdil2vemurafenibzelboraftherapyinpatientswithbrafv600mutationpositivemetastaticmelanomaproclivity01 AT danielsgregory amulticenterstudyofhighdosealdesleukinproleukinhdil2vemurafenibzelboraftherapyinpatientswithbrafv600mutationpositivemetastaticmelanomaproclivity01 AT tabackbret amulticenterstudyofhighdosealdesleukinproleukinhdil2vemurafenibzelboraftherapyinpatientswithbrafv600mutationpositivemetastaticmelanomaproclivity01 AT aungsandra amulticenterstudyofhighdosealdesleukinproleukinhdil2vemurafenibzelboraftherapyinpatientswithbrafv600mutationpositivemetastaticmelanomaproclivity01 AT lowderjames amulticenterstudyofhighdosealdesleukinproleukinhdil2vemurafenibzelboraftherapyinpatientswithbrafv600mutationpositivemetastaticmelanomaproclivity01 AT lawsondavid amulticenterstudyofhighdosealdesleukinproleukinhdil2vemurafenibzelboraftherapyinpatientswithbrafv600mutationpositivemetastaticmelanomaproclivity01 AT clarkjoseph multicenterstudyofhighdosealdesleukinproleukinhdil2vemurafenibzelboraftherapyinpatientswithbrafv600mutationpositivemetastaticmelanomaproclivity01 AT flahertylawrence multicenterstudyofhighdosealdesleukinproleukinhdil2vemurafenibzelboraftherapyinpatientswithbrafv600mutationpositivemetastaticmelanomaproclivity01 AT ernstoffmarc multicenterstudyofhighdosealdesleukinproleukinhdil2vemurafenibzelboraftherapyinpatientswithbrafv600mutationpositivemetastaticmelanomaproclivity01 AT koonhenry multicenterstudyofhighdosealdesleukinproleukinhdil2vemurafenibzelboraftherapyinpatientswithbrafv600mutationpositivemetastaticmelanomaproclivity01 AT milhemmohammed multicenterstudyofhighdosealdesleukinproleukinhdil2vemurafenibzelboraftherapyinpatientswithbrafv600mutationpositivemetastaticmelanomaproclivity01 AT militellogerald multicenterstudyofhighdosealdesleukinproleukinhdil2vemurafenibzelboraftherapyinpatientswithbrafv600mutationpositivemetastaticmelanomaproclivity01 AT agarwalasanjiv multicenterstudyofhighdosealdesleukinproleukinhdil2vemurafenibzelboraftherapyinpatientswithbrafv600mutationpositivemetastaticmelanomaproclivity01 AT curtibrendan multicenterstudyofhighdosealdesleukinproleukinhdil2vemurafenibzelboraftherapyinpatientswithbrafv600mutationpositivemetastaticmelanomaproclivity01 AT cranmerlee multicenterstudyofhighdosealdesleukinproleukinhdil2vemurafenibzelboraftherapyinpatientswithbrafv600mutationpositivemetastaticmelanomaproclivity01 AT laochristopherd multicenterstudyofhighdosealdesleukinproleukinhdil2vemurafenibzelboraftherapyinpatientswithbrafv600mutationpositivemetastaticmelanomaproclivity01 AT logantheodoref multicenterstudyofhighdosealdesleukinproleukinhdil2vemurafenibzelboraftherapyinpatientswithbrafv600mutationpositivemetastaticmelanomaproclivity01 AT lutzkyjose multicenterstudyofhighdosealdesleukinproleukinhdil2vemurafenibzelboraftherapyinpatientswithbrafv600mutationpositivemetastaticmelanomaproclivity01 AT rudrapatnavenkatesh multicenterstudyofhighdosealdesleukinproleukinhdil2vemurafenibzelboraftherapyinpatientswithbrafv600mutationpositivemetastaticmelanomaproclivity01 AT danielsgregory multicenterstudyofhighdosealdesleukinproleukinhdil2vemurafenibzelboraftherapyinpatientswithbrafv600mutationpositivemetastaticmelanomaproclivity01 AT tabackbret multicenterstudyofhighdosealdesleukinproleukinhdil2vemurafenibzelboraftherapyinpatientswithbrafv600mutationpositivemetastaticmelanomaproclivity01 AT aungsandra multicenterstudyofhighdosealdesleukinproleukinhdil2vemurafenibzelboraftherapyinpatientswithbrafv600mutationpositivemetastaticmelanomaproclivity01 AT lowderjames multicenterstudyofhighdosealdesleukinproleukinhdil2vemurafenibzelboraftherapyinpatientswithbrafv600mutationpositivemetastaticmelanomaproclivity01 AT lawsondavid multicenterstudyofhighdosealdesleukinproleukinhdil2vemurafenibzelboraftherapyinpatientswithbrafv600mutationpositivemetastaticmelanomaproclivity01 |